Viral Safety of Cell Banks: Replacing Animal-Based Assays by One Single GMP Transcriptomic Test
Webinar Date/Time: Tue, May 14, 2024 1:00 PM EDT
Just how close to singularity is the use of NGS in biosafety testing to replace animal assays?
Register Free: https://www.biopharminternational.com/bp_w/transcriptomic-test
Event Overview:
After much anticipation, the revision to ICH Q5A (R2) was finally released in November 2023, ending a multi-year wait to see how a new technology like next generation sequencing (NGS) would finally be positioned in biosafety testing. Much to the relief of those already using NGS as a platform technology in this arena, NGS was finally green-lit as an advanced testing tool and ethical replacement for two mandatory animal-based assays: in vivo adventitious virus and mouse/hamster/rat antibody production (MAP/HAP/RAP) tests.
Despite this positioning, many questions in the industry seem to remain. For example, what is the actual sensitivity of any given NGS test method? Are these assays robust enough to detect a full range of viruses? Does detection correlate with infection? And more importantly, can NGS be used to replace more than these animal-based tests in a single test?
Quite simply, just how close is NGS to becoming the singular platform to replace the current spectrum of animal through molecular-based biosafety tests? Understanding where we stand today with current advancements and comparability tests using NGS to address these questions is critical.
Key Learning Objectives:
- Regulatory framework in viral safety surrounding NGS adoption
- Holistic understanding of role of NGS in biosafety testing
- Current data supporting NGS sensitivity and robustness versus in vivo tests
- Benefits of NGS GMP transcriptomic assay over animal-based conventional methods
Who Should Attend:
- CMC Managers
- Consultants
- Chief Technical Officers
- QC Managers
- R&D Managers
- Bioprocess Development Managers
- Scientists
- Scientific Directors
- Upstream or Downstream Development Managers
- CEOs
- Directors of Cell Culture Development
Speaker:
Colette Côté, PhD
US General Manager, Chief Scientific and Portfolio Officer
PathoQuest
Dr Côté joined PathoQuest's US subsidiary as General Manager and Chief Scientific and Portfolio Officer in March 2021. Prior to this, she was Head of NGS R&D Testing Services at MilliporeSigma. Dr Côté received a PhD in Molecular Biology, Cell Biology, and Biochemistry from Brown University and was a post-doctoral fellow in the Genetics and Biochemistry branch of the National Institutes of Health (NIH).
Register Free: https://www.biopharminternational.com/bp_w/transcriptomic-test
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
